- Home
- TOMZ vs KPRX Comparison
TOMZ vs KPRX Comparison
Compare TOMZ & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOMZ | KPRX |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Diversified Commercial Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.7M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | TOMZ | KPRX |
|---|---|---|
| Price | $0.81 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 192.0K | 23.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $1.76 |
| 52 Week High | $1.20 | $3.29 |
Technical Indicators
Market Signals| Indicator | TOMZ | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 53.22 |
| Support Level | $0.69 | $2.47 |
| Resistance Level | $1.11 | $2.72 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 67.78 | 65.63 |
Price Performance
Historical ComparisonAbout TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.